bioRxivNeurosciencePreprint
A multiplex platform to identify mechanisms and modulators of proteotoxicity in neurodegeneration
Samuel J. ResnickiD, Seema QamariD, Jenny Sheng, Lei Haley HuangiD, Jonathon Nixon‐AbelliD, Schuyler M. MeloreiD, Chyi Wei ChungiD, Xuecong LiiD, Jingshu WangiD, Nancy Ruonan ZhangiD, Neil A. ShneideriD, Clemens F. KaminskiiD, Francesco Simone RuggeriiD, Gabriele S. Kaminski SchierleiD, Peter St George‐HyslopiD, Alejandro ChaveziD
Abstract
Neurodegenerative disorders are a family of diseases that remain poorly treated despite their growing global health burden. A shared feature of many neurodegenerative disorders is the accumulation of toxic misfolded proteins. To gain insight into the mechanisms and modulators of protein misfolding, we developed a multiplex reverse genetics platform. Using this novel platform 29 cell-based models expressing proteins that undergo misfolding in neurodegeneration were probed against more than a thousand genetic modifiers. The resulting data provide insight into the nature of modifiers that act on multiple misfolded proteins as compared to those that show activity on only one. To illustrate the utility of this platform, we extensively characterized a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 is a general modifier of the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs), including FUS, TDP-43, and hnRNPA1. Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 support the critical importance for DNAJB6 phase separation in its effects on multiple RNA-binding proteins. Crucially, these studies also suggest that this property can be further tuned to generate novel variants with enhanced activity that might illuminate potential avenues for clinical translation.
- Citations
- 5
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Engineered Chimeric Proteins Functionally Replace ALS-causing Endogenous FUS and TDP-43 to Improve Neuronal Health
Miyuki Hayashi, Brigid K. Jensen, … Lin E. Guo·bioRxiv·Oct 8, 2026
- Differential roles for DNAJ isoforms in HTT-polyQ and mutant FUS aggregation modulation revealed by chaperone network screens
Kinneret Rozales, Amal Younis, … Reut Shalgi·Nature CommunicationsPeer-reviewed·Jan 26, 2022
- A transient protein folding response targets aggregation in the early phase of TDP-43-mediated disease
Rebecca San Gil, Dana Pascovici, … Adam K. Walker·bioRxiv·Jun 21, 2023
- Targeting neuroinflammation by pharmacologic down-regulation of inflammatory pathways is neuroprotective in protein misfolding disorders.
Sydney J. Risen, Sean W. Boland, … Julie A. Moreno·ACS Chemical NeurosciencePeer-reviewed·Mar 20, 2024
- A Chemical Mutagenesis Approach to Insert Post-Translational Modifications in Aggregation-Prone Proteins
Y. Ge, A. Masoura, … F. A. Aprile·bioRxiv·Jan 28, 2022
- Overexpression of DnaJ chaperones in ameliorating toxicities associated with FUS and TDP-43
Snehal Ahire, Tania Bose·bioRxiv·May 28, 2025